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Natural killer (NK) cells play an essential role in the
defense against influenza virus, one of the deadliest
respiratory viruses known today. The NKp46 recep-
tor, expressed by NK cells, is critical for controlling
influenza infections, as influenza-virus-infected cells
are eliminated through the recognition of the viral
hemagglutinin (HA) protein by NKp46. Here, we
describe an immune-evasion mechanism of influ-
enza viruses that is mediated by the neuraminidase
(NA) protein. By using various NA blockers, we
show that NA removes sialic acid residues from
NKp46 and that this leads to reduced recognition of
HA. Furthermore, we provide in vivo and in vitro evi-
dence for the existence of this NA-mediated, NKp46-
dependent immune-evasion mechanism and dem-
onstrate that NA inhibitors, which are commonly
used for the treatment of influenza infections, are
useful not only as blockers of virus budding but
also as boosters of NKp46 recognition.INTRODUCTION
Influenza viruses are responsible for most respiratory infections,
affecting all age groups (Thompson et al., 2004). In influenza-
virus-infected cells, the assembly and budding of progeny vi-
ruses is the final and critical step in the life cycle of the virus
(Rossman and Lamb, 2011). This step requires the coordinated
localization of the viral hemagglutinin (HA) and neuraminidase
(NA) proteins to lipid raft domains (Nayak et al., 2004; Wang
et al., 2007), which allows the virus to acquire these glycopro-
teins by simply budding through the host cell membrane (Rifkin
and Quigley, 1974). To complete the viral budding, the viral NA
enzyme cleaves sialic acid residues that attach the progeny virus
to the infected cells (Nayak et al., 2004).1044 Cell Reports 3, 1044–1050, April 25, 2013 ª2013 The AuthorsHA is recognized by natural killer (NK) cells through their cyto-
toxic receptors NKp44 and NKp46, either on the infected cells or
when the virus adheres to the cells, and this recognition leads to
sialic-acid-dependent, NKp44/NKp46-mediated killing (Achdout
et al., 2010; Arnon et al., 2004; Ho et al., 2008; Mandelboim et al.,
2001). In vivo studies confirmed the significance of the
NKp46-HA interaction by showing that in the absence of NCR1
(NKp46 mouse orthologous protein), all NCR1-deficient mice
(Ncr1gfp/gfp) succumbed to A/Puerto Rico/8/34 influenza-virus
infection, whereas most of the wild-type (WT) mice survived
(Gazit et al., 2006; Glasner et al., 2012).
Here we demonstrate both in vitro and in vivo that influenza
viruses use their NA proteins to counter NKp46/NCR1 recogni-
tion, and that NA inhibitors, which are widely used to treat influ-
enza infections (Jefferson et al., 2009), not only affect virus
budding but also boost NKp46/NCR1 activity.
RESULTS
Assessment of NCR1 Activity against Influenza Virus
We previously showed that in the absence of NCR1, the NCR1
knockout mice (Ncr1gfp/gfp) are more sensitive to infection as
compared with their WT or heterozygous littermates (Gazit
et al., 2006; Glasner et al., 2012). To test whether the increased
sensitivity of the Ncr1gfp/gfp mice would be observed at various
doses of influenza virus, we infectedNcr1+/+ (WT) andNcr1gfp/gfp
(KO) mice with various plaque-forming units (PFU) of the
A/Puerto Rico/8/34 influenza virus. In mice infected with a low
dose (20 PFU) of the A/Puerto Rico/8/34 influenza virus, a very
mild disease developed, as all of the Ncr1gfp/gfp and Ncr1+/+
mice survived the infection (Figure 1A). When a higher dose
was applied (400 PFU), a more severe disease developed, and
differences were seen in the survival of the Ncr1+/+ mice
compared with the Ncr1gfp/gfp mice (Figure 1A, middle). When
800 PFU were administered, all mice died due to the infection
(Figure 1A).
We also analyzed the virus titers in the infected lungs.When 20
PFU were administered, low virus titers were detected in the
Figure 1. The Absence of NCR1 Affects Influenza Infection at a Certain Dose
(A and B) Survival rate (A) and viral titers in the lungs (B, log scale) were evaluated in Ncr1+/+ mice (WT) and Ncr1gfp/gfp mice (KO) following infection with the
A/Puerto Rico/8/34 influenza virus at various PFU (indicated in the figure). Virus titers in the lungs were determined at various DPIs (days postinfection). The figure
shows one representative experiment out of two performed. Statistically significant differences are indicated (*p < 0.05, **p < 0.01). The break in the x axis in-
dicates that all mice that survived the infection stayed healthy. In (B), mean values and SD are shown. In (A) and (B), the x axis indicates DPI.lungs, and in mice infected with 800 PFU, high virus titers were
detected at all time points irrespective of whether NCR1 was
present (Figure 1B). In contrast and in agreement with the sur-
vival data (Figure 1A), in mice infected with 400 PFU, differences
in the virus titers were detected between the Ncr1gfp/gfp and
Ncr1+/+ mice at all time points tested (Figure 1B).
Because we observed that the differences in lethality and virus
titers in the absence of NCR1 were only noted at a particular
dose of infection and that at slightly higher viral titers the
absence of NCR1 had no effect, and because viruses often
develop various means to counterattack important antiviral
immune mechanisms, we hypothesized that influenza virus-
es might have developed mechanisms to interfere with
NKp46/NCR1-HA recognition and that following the neutraliza-
tion of these mechanisms, NKp46/NCR1 would be able to better
control influenza infections.
NA Impairs NKp46/NCR1 Recognition of Influenza
Viruses
We previously showed that sialic acid residues attached to the
human NKp46/NCR1 are essential for their interactions with
HA (Achdout et al., 2010; Arnon et al., 2004; Glasner et al.,
2012). Because the viral NA glycoprotein removes sialic acid res-
idues, we wondered whether NA counters the HA recognition of
NKp46/NCR1 by removing their sialic acid residues. To address
this issue, we examined the binding of NKp46-immunoglobulin
(NKp46-Ig) to A/Puerto Rico/8/34-infected Jeg3 cells following
treatment with the NA inhibitor oseltamivir phosphate. As re-
ported previously (Achdout et al., 2010), in the absence of influ-
enza, little or no NKp46-Ig binding was observed (data not
shown). However, upon infection, Jeg3 cell expression of bothCHA and NA was detected and NKp46-Ig staining was noticed
(Figure 2A, left histogram and data not shown). Importantly, the
binding of NKp46-Ig was significantly enhanced following inhibi-
tion of NA activity with oseltamivir phosphate, oseltamivir
carboxylate, or zanamivir, or after blocking with anti-NA mono-
clonal antibody (mAb; Figure 2A).
The NKp46 receptor contains two extracellular C2-type Ig-like
domains: a membrane-distal domain (D1) and a membrane-
proximal domain (D2). The latter was shown to contain the sialic
acid residue (Thr 225), which is essential for HA-NKp46 recogni-
tion (Arnon et al., 2004). Thus, to further corroborate our results,
we generated truncated versions of NKp46 protein that con-
tained the membrane-distal domain (D1-Ig) or the membrane-
proximal domain including the stalk region (D2-Ig) of NKp46
fused to human IgG1. Using these fusion proteins, we observed
increased binding of D2-Ig to influenza-virus-infected cells that
were treated with NA inhibitors (Figure 2B). A similar effect was
observed when the cells were stained with NCR1-Ig (Figure 2C),
but no binding was observed when D1-Ig was used (Figure 2D).
To control our experiments, we stained both treated and un-
treated influenza-virus-infected cells with an anti-influenza virus
type A HA mAb and with a fusion protein that contains the extra-
cellular domain of the NK inhibitory receptor LIR1 (LIR1-Ig). We
observed that untreated and treated cells were similarly recog-
nized by anti-HA mAb and LIR1-Ig (Figure 2E).
The A/Puerto Rico/8/34 virus (H1N1) is a human virus that has
been adapted for mouse studies. This virus is able to bind both
Neu5NAca(2,3) and Neu5NAca(2,6), sialic acid residues that
are found on NKp46 (Mendelson et al., 2010). Because most hu-
man viruses preferentially interact with Neu5NAca(2,6) sialic acid
residues, it was important to test whether similar results wouldell Reports 3, 1044–1050, April 25, 2013 ª2013 The Authors 1045
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be obtained with human viruses. To that end, we tested
NKp46-Ig binding to the influenza A/Texas/1/1977 (H3N2) virus.
We used this virus to infect mouse EL4 cells because we
observed that in some tumor cells that express an unknown
tumor ligand for NKp46 (such as EL4), binding of NKp46-Ig is
not observed following infection (Figure 2F and data not shown).
We reasoned that this is because the expression of the unknown
tumor ligand for NKp46 is already quite high, and thus upon
infection with influenza, the binding of NKp46 to HA cannot be
detected. We further thought that upon oseltamivir carboxylate
treatment, we might be able to observe the HA-NKp46
interactions.
To test the above hypotheses, EL-4 cells were infected with
the A/Texas/1/1977 (H3N2) influenza virus, treated or not with
oseltamivir carboxylate, and incubated with NKp46-Ig at 4C
and 37C. Importantly, upon oseltamivir carboxylate treatment,
the binding of NKp46 to the A/Texas/1/1977-infected cells was
significantly increased (Figure 2F). Interestingly, the increased
binding of NKp46 to A/Texas/1/1977-infected cells (Figure 2F)
and A/Puerto Rico/8/34-infected cells (Figures 2A–2E) following
NA inhibition was observed at 4C, even though this temperature
decreases the enzymatic activity of NA. We expected, however,
that at 37C the NA activity would be more prominent, and
indeed when the A/Texas/1/1977-infected cells were treated
with oseltamivir carboxylate and incubated at 37C, the
increased NKp46-Ig binding was markedly reduced compared
with incubation at 4C (Figure 2F), probably because the oselta-
mivir carboxylate treatment (at this dose) was insufficient to
inhibit the fully active NA enzyme.
To further demonstrate that anti-NA drugs boost the NKp46-Ig
recognition of infected cells, we treated influenza-virus-infected
cells with two concentrations of oseltamivir phosphate or oselta-
mivir carboxylate. At a concentration of 10 mg/ml, both drugs
enhanced the NKp46-Ig binding (Figure S1), whereas at a con-
centration of 10 ng/ml, increased NKp46-Ig binding was
observed only with oseltamivir carboxylate (which is more active
than oseltamivir phosphate; Lindemann et al., 2010).
NA Impairs the Direct Interaction between HA and
NKp46/NCR1 by Removing their Sialic Acid Residues
We next tested whether NA treatment impairs the interaction
between NKp46/NCR1 and HA by reducing the sialic acid con-
tent of these two receptors. For this, we generated an additional
fusion protein in which the extracellular portion of the HA protein
(A/Puerto Rico/8/34) was fused to the human IgG1 Fc domain
(HA-Ig). We verified by western blotting that all fusion proteins
were highly purified, had the correct size, andwere not degraded
by the use of anti-human Fc antibodies (Figure 3A, left panel) orFigure 2. Increased Binding of NKp46/NCR1 to Infected Cells followin
(A–D) FACS staining of infected cells. Staining was performed with NKp46-Ig (A),
show the staining of the infected cells treated with control antibody (12E7), and
phosphate, oseltamivir carboxylate, zanamivir, or anti-NA mAb (NA2-1C1). The v
depict staining with the indicated fusion protein. The median fluorescent intensit
(E) FACS analysis of infected cells stained with anti-HA mAb (left histogram) or L
staining of the untreated cells with the indicated fusion protein, and the empty bla
(F) FACS analysis of A/Texas/1/1977-infected EL-4 cells stained with NKp46-Ig at
parts the staining is presented after gating of the live-cell population only, and the
shows representative staining, and four independent experiments were performe
Canti-HA antibody (Figure 3A, right panel). NKp46-Ig and NCR1-Ig
were then treated with NA in the presence or absence of oselta-
mivir carboxylate and run on SDS-PAGE gels. We previously
demonstrated that a2,6-linked sialic acid residues are important
for NKp46-HA recognition (Arnon et al., 2004). We therefore per-
formed western blotting using Sambucus nigra agglutinin (SNA)
lectin, which preferentially binds these residues. As can be seen
in Figures 3B and 3C, the NA treatment significantly reduced the
binding of SNA lectin to NKp46-Ig and NCR1-Ig as compared
with the untreated proteins. Inhibition of NA activity by oseltami-
vir carboxylate restored the SNA lectin binding to both proteins
(Figures 3B and 3C).
NA treatment of almost any protein will result in reduced sialic
acid content. However, most sialylated proteins we have tested
are unable to interact with HA (Arnon et al., 2001; Mandelboim
et al., 2001). Therefore, it was important to demonstrate that
the removal of sialic acid residues fromNKp46/NCR1will directly
affect HA recognition. To demonstrate this, the proteins were
treated with NA as above, in the presence or absence of oselta-
mivir carboxylate, run on SDS-PAGE gels, and western blotted
with biotinylated HA-Ig. Importantly, we observed that the direct
interaction between HA and NKp46 (Figure 3D) or NCR1 (Fig-
ure 3E) was impaired upon NA treatment and restored when
NA inhibitors were added.
NA Impairs NKp46/NCR1 Activity In Vitro and In Vivo
To test whether blocking of NA activity would directly affect the
killing of influenza-virus-infected cells, we performed NK cyto-
toxicity assays using the Jeg3 cell line, which is negative for
known NK ligands (Achdout et al., 2010) and human NK cells.
In the absence of infection, only minimal killing of Jeg3 cells
was observed, and following influenza infection, NK killing was
detected (Figures 4A–4D). Importantly, when infected cells
were pretreated with oseltamivir phosphate (Figure 4A), oselta-
mivir carboxylate (Figure 4B), or an anti-NA mAb (Figure 4C), a
significant increase in NK cytotoxicity was observed. In contrast,
preincubation of the infected cells with a control mAb (12E7) had
no effect (Figure 4D).
We also tested whether oseltamivir carboxylate treatment
would affect the NCR1-Ig binding and mouse NK killing of EL4
cells infected with A/Puerto Rico/8/34 influenza virus (we used
A/Puerto Rico/8/34 because it was used later in the in vivo as-
says). As seen for the NKp46-Ig staining (Figure 2F), upon infec-
tion, little or no change in the binding of NCR1-Ig to the infected
cells was observed (Figure 4E and data not shown). However,
upon oseltamivir carboxylate treatment, the binding of NCR1-Ig
was markedly enhanced (Figure 4E). We next performed NK cell
cytotoxicity assays using mouse NK cells derived from Ncr1+/+g Blocking of NA Activity
D2-Ig (B), NCR1-Ig (C), and D1-Ig (D). In each part of the figure, the left panels
the other panels show the staining of infected cells treated with oseltamivir
arious treatments are indicated above the figure. The empty black histograms
y (MFI) of each staining is indicated in the histograms. See also Figure S1.
IR1-Ig (right histogram). In each panel, the empty gray histogram depicts the
ck histogram depicts the staining following oseltamivir carboxylate treatment.
4C and at 37Cwith andwithout oseltamivir carboxylate treatment. In all figure
filled gray histograms depict staining with the secondary mAb only. The figure
d.
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Figure 3. The Removal of Sialic Acid Residues from NKp46/NCR1
Reduces HA Recognition
(A) NCR1-Ig, NKp46-Ig, and HA-Ig were western blotted with biotinylated anti-
human IgG1 Fc antibodies (left panel) and an anti-influenza virus type A (H1)
mAb (right panel).
(B–E) NKp46-Ig (B and D) and NCR1-Ig (C and E) proteins were incubated with
and without NA beads, in the presence or absence of oseltamivir carboxylate.
The proteins were western blotted with SNA lectin (B and C) or HA-Ig (D and E).
The figure shows the quantification (in arbitrary units) of the relative intensity of
the binding. Representative results from three independent experiments are
shown. Shown aremean values and SD. Statistically significant differences are
indicated (*p < 0.05, **p < 0.01).(WT) andNcr1gfp/gfp (KO) mice. When NK cells were derived from
the Ncr1gfp/gfp mice, only minimal killing of the infected cells was
observed and the level of killing was not affected by oseltamivir
carboxylate treatment (Figure 4F). In contrast, when NK cells
were derived from Ncr1+/+ mice, killing of the infected cells
was observed and, importantly, it was enhanced following osel-
tamivir carboxylate treatment (Figure 4F).
In our final set of experiments, we evaluated the NA effect
in vivo and infected Ncr1+/+ (WT) and Ncr1gfp/gfp (KO) mice
with various doses of A/Puerto Rico/8/34 virus. At 800 PFU (a
dose that causes equal lethality in both Ncr1gfp/gfp and
Ncr1+/+ mice [Figure 1]), 10 days postinfection (DPI) all un-
treated mice (both Ncr1+/+ and Ncr1gfp/gfp) died due to the infec-
tion (Figure 4G). Importantly, when the mice were treated with1048 Cell Reports 3, 1044–1050, April 25, 2013 ª2013 The Authorsoseltamivir carboxylate (Tamiflu), 83% of the Ncr1+/+mice sur-
vived the infection, whereas only 33% of the Ncr1gfp/gfp mice
remained alive (Figure 4G). Similar differences between the
Ncr1gfp/gfp and Ncr1+/+mice were observed even when a
10-fold higher viral dose (8 3 103 PFU) was administered
(Figure 4H). When 100-fold more virus (8 3 104 PFU) was
administered, the NKp46 effect was no longer seen, the disease
progression was extremely rapid and all mice died at 6 or 7 DPI
(Figure 4I).DISCUSSION
We started this investigation because we were surprised to see
that the absence of NCR1 affected mouse mortality and virus
titers in the lungs only at a certain dose of the influenza virus.
We hypothesized that the influenza virus developedmechanisms
to counter the NKp46/NCR1 recognition of HA and that this
might impair NK-mediated killing, similarly to the effect seen in
HSV-1 infections, in which the viral evasion from complement-
mediated neutralization masks the effect of knocking down the
complement component C3 (Lubinski et al., 1998). Indeed, we
have demonstrated here that NA removes sialic acid residues
from NKp46/NCR1 and that this results in reduced recognition
of HA. Furthermore, we showed that when the NA activity is
blocked in vivo, the NCR1 effect is observed over a range of virus
titers. We thus provide in vivo evidence that NA inhibitors exert
their effect not only by inhibiting the release of virus progeny
from the infected cells but also by enhancing NKp46-mediated
elimination of infected cells. Interestingly, it was recently demon-
strated in vitro that NA inhibitors have additional immune-related
properties, because they facilitate the ability of innate immune
proteins such as ficolins to inhibit viral infectivity (Verma et al.,
2012). Taken together, these results suggest that NA inhibitors
may have several beneficial effects in the defense against influ-
enza infection.
The main influenza virus strain used in this research was
A/Puerto Rico/8/34 (H1N1). Because of the special characteris-
tics of this virus strain, it was important to verify our findings with
another human virus strain. Importantly, similar findingswere ob-
tained when the human influenza virus A/Texas/1/1977 (H3N2)
was used, indicating that NKp46 interacts with several HAs
and that the NA-based immune-evasion mechanism is a general
mechanism that is shared by different influenza viruses and NA
subtypes.
NA inhibitors, such as oseltamivir (Tamiflu), are widely used to
treat influenza infections. Unfortunately, the virus evades the ac-
tivity of those drugs by mutating the NA active site (Dolin, 2011).
Thus, our results not only provide an insight into influenza virus
immune-evasion mechanisms, they may also provide the infor-
mation needed to develop more efficient drugs that will better
target NA and at the same time more efficiently boost NKp46-
mediated killing.EXPERIMENTAL PROCEDURES
Cells and Viruses
The cell lines used in this study were the human choriocarcinoma cell line
Jeg3 and the mouse lymphoma cell line EL4. The influenza viruses A/Puerto
Figure 4. Blocking of NA Boosts NKp46/NCR1 Activity
(A–D) InfectedJeg3cells thatwerenot treatedor treatedwithvariousNA inhibitors (oseltamivir phosphate [A],oseltamivir carboxylate [B], anti-NAmAb [C]) andcontrol
mAb (D) were tested in killing assays. The effector-to-target ratio (E:T) is indicated in the x axis. Shown are mean values and SD derived from triplicates. Statistically
significant differences are indicated (*p < 0.05, **p < 0.01 or ***p < 0.005). The figure shows the results of one representative experiment out of three performed.
(E) Infected EL4 cells treated (gray empty histogram) or not (black empty histogram) with oseltamivir carboxylate were stained with NCR1-Ig. The filled gray
histogram depicts staining with the secondary mAb only.
(F) Infected EL4 cells treated or not with oseltamivir carboxylate were tested in killing assays against mouse NK cells isolated from Ncr1+/+ (WT) and Ncr1gfp/gfp
mice (depicted in the figure as NCR1/ [KO] mice). The E:T is indicated in the x axis. Shown are mean values and SD derived from triplicates. Statistically
significant differences are indicated (*p < 0.05, **p < 0.01). The experiment was repeated twice.
(G–I) Percent survival of Ncr1+/+ and Ncr1gfp/gfp mice infected with 800 PFU (G), 83 103 PFU (H), or 83 104 PFU (I) of A/Puerto Rico/8/34 influenza virus, treated
with oseltamivir phosphate (Tamiflu) or mock treated. The experiment was repeated twice. Statistically significant differences are indicated (*p < 0.05). The x axis
indicates DPI. The break in the x axis indicates that all mice that survived the infection stayed healthy.Rico/8/34 (H1N1) and A/Texas/1/1977 (H3N2) were grown in eggs as previ-
ously described (Achdout et al., 2003). Viral titers were determined by using
quantitative RT-PCR (qRT-PCR), a method used for the detection of influenza
virus in patients (Hindiyeh et al., 2005).
Fusion Proteins and Compounds
NKp46-Ig, D2-Ig, D1-Ig, NCR1-Ig, and LIR1-Ig fusion proteins were produced
as previously described (Arnon et al., 2004). For generation of the HA-Ig
fusion protein, the extracellular domain of the A/Puerto Rico/8/34-HA was
cloned in frame with human IgG1 Fc to a mammalian expression vector con-
taining the Fc portion of human IgG1.The HA-Ig protein used in the western
blot experiments was biotinylated (21331; Thermo Scientific). The NA inhibi-
tors used were oseltamivir phosphate (Tamiflu; F. Hoffmann-La Roche),
oseltamivir carboxylate (sc-212484; Santa Cruz), and zanamivir (sc-208495;
Santa Cruz).CFluorescence-Activated Cell Sorting Staining
For all fluorescence-activated cell sorting (FACS) staining, cellswere incubated
for 1hr or overnightwith thedifferent influenza virus strains at a ratioof 500PFU/
103 cells at 37C. The cellswere thenwashed and incubated on ice (unless indi-
cated otherwise) with the appropriate fusion protein (5 mg/well) for 2 hr. For NA
inhibition assays, the cells were incubated for 1 hr or overnightwith the different
influenza virus strains at a ratio of 500PFU/103 cells at 37C,washed, and incu-
bated for 1 hr on ice with 5 mg/ml of anti-NAmAb orwith 10 ng/ml to 10 mg/ml of
NA inhibitors, and then stained with the appropriate fusion proteins.
Western Blotting
NKp46-Ig and NCR1-Ig were incubated for 2 hr with NA beads (Sigma) at a ra-
tio of 2 ml beads/1 mg protein. For NA inhibition, NA beads were pretreated with
50 ml of oseltamivir carboxylate (10 ng/ml to 10 mg/ml). Samples (3 mg) were run
on 10% SDS-PAGE gels in reducing conditions and blotted with 20 mg/ml ofell Reports 3, 1044–1050, April 25, 2013 ª2013 The Authors 1049
biotinylated SNA lectin (Vector Laboratories) or with biotinylated HA-Ig
(4 mg/ml) and then incubated with Avidin-HRP (Bio Legend). The nontreated
NKp46-Ig or NCR1-Ig proteins were used as control. NKp46-Ig, NCR1-Ig,
and HA-Ig were also blotted with biotinylated anti-human Fc antibody
(Jackson ImmunoResearch) and anti-influenza virus type A (H1) mAb.
Cytotoxicity Assay
The cytotoxic activity of human NK cells against various targets was assessed
in 5 hr 35S release assays as previously described (Mandelboim et al., 1996).
For NA inhibition, cells were incubated overnight with the different influenza
virus strains at a ratio of 500 PFU/103 cells at 37C and treated with 0.5 mg
of anti-NA mAb or with 1–10 mg/ml of NA inhibitors. Mouse NK cells were iso-
lated from WT and Ncr1gfp/gfp mice 18 hr following i.p. injection of 200 mg
poly(I):poly(C) (P1530; Sigma).
Infection of Mice and Oseltamivir Treatment
Ncr1+/+ (WT) and Ncr1gfp/gfp (KO) female mice (4–6 weeks old) were infected
intranasally with various PFU of the A/Puerto Rico/8/34 virus. Each group con-
tained at least eight mice. For Tamiflu treatment, mice were treated orally with
50 ml of 10 mg/ml oseltamivir phosphate (Tamiflu) diluted in double deionized
water (DDW) or with DDW only as control. The first treatment was given 3 hr
after infection. The Tamiflu treatment was then given twice a day at 12 hr inter-
vals for 3 days, and later at 6 DPI.
Statistical Methods
Student’s t test and log rank test (for the survival experiments) were used to
determine significant differences.
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